Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds

  • 📰 NewsfromScience
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 51%

Law Law Headlines News

Law Law Latest News,Law Law Headlines

Baricitinib, a drug commonly used by people with rheumatoid arthritis, reduced hospitalized COVID19 patients’ risk of dying by 13% when taken with other proven COVID-19 drugs.

. Now, baricitinib reduces deaths even further. “This is a drug that is just as effective as tocilizumab,” Landray says. “The effect size is very similar.”

But the rise of the Omicron variant of SARS-CoV-2 has also challenged progress in treating COVID-19. Several antibody treatments are ineffective against this variant, which now dominates infections across the globe. In its recent guideline update, WHO recommended that an antibody cocktail, casirivimab-imdevimab, only be given when a different variant has caused an infection.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

巴瑞替尼片

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 515. in LAW

Law Law Latest News, Law Law Headlines